Scientific Research Publishing

Advances in Bioscience and Biotechnology, 2024, 15, 406-431
https://www.scirp.org/journal/abb
ISSN Online: 2156-8502
ISSN Print: 2156-8456

Evaluating Pharmacological and Rehabilitation Strategies for Effective Management of Bipolar Disorder: A Comprehensive Clinical Study

Rocco de Filippis[1*], Abdullah Al Foysal[2]

[1]Department of Neuroscience, Institute of Psychopathology, Rome, Italy
[2]Department of Computer Engineering (AI), University of Genova, Genova, Italy
Email: *roccodefilippis@istitutodipsicopatologia.it, niloyhasanfoysal440@gmail.com

How to cite this paper: de Filippis, R. and Al Foysal, A. (2024) Evaluating Pharmacological and Rehabilitation Strategies for Effective Management of Bipolar Disorder: A Comprehensive Clinical Study. *Advances in Bioscience and Biotechnology*, **15**, 406-431.
https://doi.org/10.4236/abb.2024.157025

Received: June 26, 2024
Accepted: July 23, 2024
Published: July 26, 2024

Abstract

Bipolar disorder presents significant challenges in clinical management, characterized by recurrent episodes of depression and mania often accompanied by impairment in functioning. This study investigates the efficacy of pharmacological interventions and rehabilitation strategies to improve patient outcomes and quality of life. Utilizing a randomized controlled trial with multiple treatment arms, participants will receive pharmacotherapy, polypharmacotherapy, rehabilitation interventions, or combination treatments. Outcome measures will be assessed using standardized scales, including the Hamilton Depression Scale, Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Mania Scale. Preliminary data suggest improvements in symptom severity and functional outcomes with combination treatments. This research aims to inform clinical practice, guide treatment decisions, and ultimately enhance the quality of care for individuals living with bipolar disorder. Findings will be disseminated through peer-reviewed journals and scientific conferences to advance knowledge in this field.

Keywords

Bipolar Disorder (BD), Pharmacotherapy (PT), Rehabilitation Interventions (RI), Hamilton Depression Scale (HAM-D), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Mania Scale (MS), Machine learning (ML) and Artificial Intelligence (AI).

1. Introduction

Bipolar disorder is a complex and debilitating psychiatric illness characterized by

recurrent episodes of mood disturbances, including manic, hypomanic, and depressive episodes [1]. It affects approximately 2% - 3% of the global population and is associated with significant morbidity and mortality if left untreated or improperly managed [2]. The disorder presents unique challenges in clinical practice due to its chronic and relapsing nature, variability in symptom presentation, and considerable heterogeneity in treatment response among individuals. Despite advances in pharmacotherapy and psychosocial interventions, the optimal management of bipolar disorder remains elusive, with a substantial proportion of patients experiencing persistent symptoms, functional impairment, and a high risk of relapse. Moreover, the co-occurrence of comorbid conditions, such as anxiety disorders and substance use disorders, further complicates treatment outcomes and underscores the need for comprehensive and individualized approaches to care. In recent years, there has been growing interest in exploring the role of polypharmacotherapy and rehabilitation strategies in the treatment of bipolar disorder. Polypharmacotherapy involves the concurrent use of multiple medications targeting different aspects of the illness, aiming to enhance efficacy and tolerability while minimizing adverse effects [3]. Rehabilitation interventions encompass a range of psychosocial and occupational therapies designed to improve functional outcomes, enhance coping skills, and promote recovery [4]. While existing research has provided valuable insights into the effectiveness of pharmacological and psychosocial interventions individually, there remains a paucity of evidence on the comparative efficacy of different treatment modalities and their integration into comprehensive treatment plans for bipolar disorder [5]. Furthermore, the heterogeneity of treatment response observed in clinical practice underscores the need for personalized treatment approaches tailored to the specific needs and preferences of individual patients [6].

This study aims to fill existing knowledge gaps by evaluating the efficacy of pharmacological and rehabilitation strategies in treating bipolar disorder. Using a randomized controlled trial with multiple treatment arms, we will compare the effectiveness of pharmacotherapy, polypharmacotherapy, rehabilitation interventions, and their combinations. The primary goals are to reduce symptom severity, enhance functional outcomes, and improve quality of life. This research will inform evidence-based practices, guide treatment decisions, and contribute to optimizing care for individuals with bipolar disorder. Findings will be shared through peer-reviewed journals and scientific conferences to advance knowledge and improve patient care.

2. Study Design and Protocol Development

Bipolar disorder represents a complex psychiatric condition characterized by recurrent episodes of mood disturbance, including manic and depressive episodes [7]. The proposed study aims to investigate the efficacy of various treatment approaches, including pharmacotherapy, polypharmacotherapy, rehabilitation interventions, and their combinations, in managing symptoms and improving functional outcomes in individuals diagnosed with bipolar disorder.

2.1. Define Inclusion and Exclusion Criteria

Inclusion Criteria:

*Adults aged 18 - 65 years diagnosed with bipolar disorder type I or II according to DSM-5 criteria [8] [9]. *Currently experiencing a mood episode (depressive, manic, or mixed) or in a stable phase but with a history of recurrent mood episodes.

Exclusion Criteria:

*Presence of severe comorbid psychiatric or medical conditions that may significantly interfere with study participation or confound treatment outcomes. *History of non-response or intolerable side effects to the proposed treatment interventions. *Current pregnancy or lactation. *Inability to comply with study procedures or follow-up assessments.

2.2. Establish Treatment Arms

The study will employ a randomized controlled trial (RCT) design with participants randomized to one of the following treatment arms:

Pharmacotherapy Alone: Participants will receive standard pharmacological treatment for bipolar disorder, including mood stabilizers, antipsychotics, or antidepressants, based on current clinical guidelines and individual treatment history [10].

Polypharmacotherapy: Participants will receive a combination of multiple pharmacological agents targeting different aspects of bipolar disorder symptomatology [10]. The selection of medications and dosages will be individualized based on treatment response, tolerability, and clinician discretion.

Rehabilitation Interventions: Participants will undergo psychosocial and occupational rehabilitation interventions aimed at improving functional outcomes and promoting recovery. These may include cognitive-behavioural therapy, psychoeducation, vocational training, and social skills training [10].

Combination Treatments: Participants will receive a combination of pharmacotherapy and rehabilitation interventions, integrating both pharmacological and psychosocial approaches to treatment. Participants will be randomized to treatment arms using computer-generated randomization codes to ensure allocation concealment and minimize selection bias. Treatment assignments will be stratified based on baseline symptom severity and treatment history to ensure balanced representation across treatment groups.

2.3. Determine Outcome Measures

Outcome measures will be assessed using standardized rating scales administered at baseline and regular intervals throughout the study period [11]. The primary outcome measures will include:

Hamilton Depression Scale (HAM-D): A widely used clinician-rated scale for assessing the severity of depressive symptoms in individuals with bipolar disorder. Hamilton Depression Scale (HAM-D) [12], the HAM-D assesses depression

severity using 17 items, each rated on a scale from 0 to 4. Let Xi represent the rating for item i. The total HAM-D score H can be calculated as: $H = \sum_{i=1}^{17} Xi$

Example: If a patient's ratings for the 17 items are 2, 3, 1, 4, ..., 2, then the total HAM-D score would be the sum of these values.

Yale-Brown Obsessive Compulsive Scale (Y-BOCS): A standardized measure of obsessive-compulsive symptoms, which are commonly comorbid with bipolar disorder and may impact treatment response and functional outcomes [13]. The Y-BOCS assesses obsessive-compulsive disorder (OCD) severity with items for obsessions and compulsions. Let Oi represent the rating for obsession item i and Ci represent the rating for compulsion item i. The total Y-BOCS score Y can be calculated as: $Y = \sum_{i=1}^{5} Oi + \sum_{i=1}^{10} Ci$

Example: If a patient's ratings for obsessions are 2, 1, 3, 0, 2 and for compulsions are 3, 2, 1, 4, ..., 1, then the total Y-BOCS score would be the sum of these values.

Mania Scale: A clinician-rated scale for assessing the severity of manic symptoms in individuals with bipolar disorder. The Mania Scale assesses manic symptoms. Let M represent the mania score. Example (using Altman Self-Rating Mania Scale - ASRM): $M = \sum_{i=1}^{n} Xi$

Example: If a patient's ratings for happiness (question 1) are 4 and self-confidence (question 2) are 3, then the ASRM score would be: $M = 4 + 3 = 7$

Secondary outcome measures may include measures of functional impairment, quality of life, medication adherence, and adverse events. By employing a rigorous study design and protocol development process, this research aims to provide valuable insights into the comparative effectiveness of different treatment modalities in managing bipolar disorder symptoms and improving functional outcomes. The selection of appropriate inclusion and exclusion criteria, treatment arms, and outcome measures is crucial to ensuring the validity and generalizability of study findings and ultimately advancing evidence-based practice in the management of bipolar disorder.

3. Participant Recruitment and Informed Consent

Participant recruitment and obtaining informed consent are critical components of any research study, ensuring that participants fully understand the study's purpose, procedures, potential risks, and benefits before agreeing to participate [14]. To initiate participant recruitment, various strategies will be employed to identify individuals who meet the study's inclusion criteria. This will involve reaching out to psychiatric clinics, advertising in relevant community spaces, and potentially collaborating with healthcare providers to identify eligible participants. Screening procedures will then be implemented to confirm eligibility based on the study's inclusion criteria, which specify that participants must be adults diagnosed with bipolar disorder type I or II [15]. It's important to screen out individuals who meet any of the exclusion criteria, such as those with severe comorbid psychiatric or medical conditions, pregnant or lactating individuals, or those unable to comply with study procedures. Once potential participants

have been identified, the process of obtaining informed consent begins. Participants will be provided with detailed information about the study, including its purpose, procedures, potential risks, benefits, confidentiality measures, and their rights as participants. Researchers will ensure that this information is communicated clearly and comprehensibly, using language that is accessible to all participants. Participants will be given adequate time to review the consent form and ask any questions they may have about the study. It will be emphasized that participation is entirely voluntary, and participants have the right to withdraw from the study at any time without consequence. Written informed consent will be obtained from participants who agree to participate, with both the participant and the researcher signing and dating the consent form.

Throughout the recruitment and consent process, strict adherence to ethical guidelines will be maintained to protect the rights and well-being of participants [16]. This includes conducting the study in accordance with ethical principles outlined in guidelines such as the Declaration of Helsinki, Belmont Report, and local regulations [17]. To ensure participant safety and confidentiality, all data will be handled securely, and participant identities will be kept confidential. Prior approval for the research protocol will be obtained from an institutional review board (IRB) or ethics committee before initiating participant recruitment and data collection [18]. Additionally, researchers will adhere to all applicable laws and regulations governing research involving human participants, obtaining necessary permits and approvals as required by local authorities. By following these rigorous procedures, researchers can ensure that participant recruitment is conducted ethically, and participants provide fully informed consent before participating in the study.

4. Baseline Assessment

Before initiating any interventions or treatments, a thorough baseline assessment will be conducted for each participant enrolled in the study [19]. This assessment will involve the administration of standardized rating scales to evaluate key measures related to bipolar disorder symptoms, including depression severity, obsessive-compulsive symptoms, and manic symptoms. Specifically, the Hamilton Depression Scale (HAM-D), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Mania Scale will be administered to each participant [20]. The Hamilton Depression Scale (HAM-D) is a clinician-rated scale widely used to assess the severity of depressive symptoms in individuals with bipolar disorder [21]. It consists of 17 items, each rated on a scale from 0 to 4, with higher scores indicating greater severity of depression [22]. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a standardized measure used to assess the severity of obsessive-compulsive symptoms, which commonly co-occur with bipolar disorder [23]. The scale includes items related to both obsessions and compulsions, with separate scores for each domain [24]. The Mania Scale is a clinician-rated scale used to assess the severity of manic symptoms in individuals with bipolar disorder [25]. There are different versions of the Mania Scale, such as the

Altman Self-Rating Mania Scale (ASRM) or the Young Mania Rating Scale (YMRS), which may vary slightly in their item content and scoring [26].

By administering these rating scales at baseline, researchers can establish a comprehensive understanding of each participant's symptom profile and severity level before initiating any treatment interventions. This baseline assessment serves as a crucial reference point for evaluating treatment outcomes and tracking changes in symptom severity over time throughout the course of the study [27]. Additionally, it provides valuable data for subsequent analyses, including comparisons between treatment groups and correlations between baseline characteristics and treatment response. Overall, the baseline assessment is a fundamental step in the research process, enabling researchers to characterize the study population and inform treatment decisions based on individual symptom profiles.

5. Treatment Intervention

Following the baseline assessment, participants will be assigned to one of the predetermined treatment arms based on the randomization process [28]. The treatment arms include pharmacotherapy alone, polypharmacotherapy, rehabilitation interventions, and combination treatments [29]. Each participant will receive the designated treatment protocol according to their assigned arm. For participants allocated to the pharmacotherapy alone arm, standard pharmacological treatments for bipolar disorder will be implemented. This may include mood stabilizers, antipsychotics, or antidepressants, as per current clinical guidelines and individual treatment history. Those assigned to the polypharmacotherapy arm will receive a combination of multiple pharmacological agents targeting different aspects of bipolar disorder symptomatology. The selection of medications and dosages will be individualized based on treatment response, tolerability, and clinician discretion. Participants in the rehabilitation interventions arm will undergo psychosocial and occupational rehabilitation interventions aimed at improving functional outcomes and promoting recovery. These interventions may include cognitive-behavioural therapy, psychoeducation, vocational training, and social skills training. Individuals assigned to the combination treatments arm will receive a combination of pharmacotherapy and rehabilitation interventions, integrating both pharmacological and psychosocial approaches to treatment.

Throughout the intervention period, participants will receive ongoing monitoring and support from the research team to ensure adherence to the treatment protocols and address any concerns or adverse effects that may arise. Treatment fidelity will be maintained through regular supervision and adherence to standardized treatment protocols. By implementing these treatment interventions according to the assigned treatment arms, the study aims to evaluate the comparative effectiveness of different treatment modalities in managing bipolar disorder symptoms and improving functional outcomes. The treatment phase of the study will provide valuable insights into the efficacy and tolerability of vari-

ous treatment approaches, informing evidence-based practice in the management of bipolar disorder.

6. Follow-Up Assessments

The Hamilton Depression Scale (HAM-D) is a widely used tool in psychiatric practice to assess the severity of depressive symptoms in individuals. It comprises 17 items that cover various aspects of depression, including mood, guilt, and sleep disturbances. By administering the HAM-D periodically, clinicians can track changes in depressive symptoms over time [30]. This involves calculating the total score based on the ratings for each item, allowing clinicians to quantify the severity of depression and monitor improvements or worsening of symptoms. For instance, if a patient's HAM-D scores were 10 at baseline, 8 at week 4, and 6 at week 8, clinicians can observe a gradual reduction in depressive symptoms, indicating a positive response to treatment [31].

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is another essential assessment tool used to evaluate the severity of obsessive-compulsive symptoms in individuals with OCD [32]. It consists of items that assess both obsessions and compulsions. Regular administration of the Y-BOCS allows clinicians to monitor changes in symptom severity over time [33]. By summing the ratings for obsession and compulsion items, clinicians obtain a total score that reflects the overall severity of OCD symptoms [34]. For example, if a patient's Y-BOCS scores were 20 at baseline, 15 at week 6, and 10 at week 12, clinicians can observe a reduction in obsessive-compulsive symptoms, indicating potential treatment efficacy. Additionally, monitoring manic symptoms is crucial in individuals with bipolar disorder. Mania scales, such as the Altman Self-Rating Mania Scale (ASRM) or the Young Mania Rating Scale (YMRS), are used for this purpose [35]. Continuous assessment of manic symptoms using an appropriate scale allows clinicians to assess changes in symptom severity over time. Recording the scores at follow-up visits enables clinicians to evaluate the impact of treatment interventions on manic symptoms [36]. For instance, if a patient's ASRM score was 7 at baseline, 5 at week 2, and 3 at week 4, clinicians can observe a decrease in manic symptoms, suggesting a positive response to treatment.

Regular administration of these assessment tools and diligent tracking of symptom scores provide clinicians with valuable insights into the effectiveness of treatment interventions [37]. Through regular follow-ups, clinicians can identify trends, detect potential relapses, and make informed adjustments to therapeutic approaches to optimize treatment outcomes for individuals with bipolar disorder.

7. Data Collection and Management

Data collection and management are critical aspects of research, ensuring the accuracy, integrity, and confidentiality of collected data [38]. Researchers must adhere to stringent protocols to maintain the quality and privacy of participant information throughout the study. Accurate data collection involves systemati-

cally gathering relevant information from study participants, such as demographic details, clinical assessments, and treatment outcomes [39]. Researchers must employ standardized procedures to ensure consistency and reliability in data collection across all study participants [40]. This may involve using validated assessment tools, conducting structured interviews, or recording observations in a systematic manner. Once collected, the data must be meticulously recorded and organized to facilitate analysis and interpretation. This includes creating comprehensive databases or electronic records that capture all pertinent information in a structured format. Researchers should employ appropriate data management systems and software to streamline data entry, storage, and retrieval processes while minimizing the risk of errors or discrepancies. Ensuring data integrity is paramount to maintaining the trustworthiness and validity of study findings [41]. Researchers must implement robust quality control measures to identify and rectify any inaccuracies or inconsistencies in the collected data promptly. This may involve conducting regular audits, performing data validation checks, and verifying data accuracy against source documents. Confidentiality is a cornerstone of ethical research practice, safeguarding the privacy and anonymity of study participants. Researchers must uphold strict confidentiality protocols to prevent unauthorized access, disclosure, or misuse of participant data. This may entail implementing secure data storage systems, anonymizing or de-identifying participant information, and restricting access to authorized personnel only. Meticulous data collection and management practices are essential for maintaining the integrity and validity of research studies. By adhering to rigorous protocols and ethical guidelines, researchers can ensure the accuracy, reliability, and confidentiality of collected data, thereby enhancing the credibility and impact of their research findings.

8. Machine Learning Analysis

In the realm of scientific inquiry into bipolar disorder treatment, machine learning (ML) analysis stands as a pivotal tool for deriving insights from the collected data. By harnessing ML algorithms, researchers can uncover intricate patterns and relationships within the dataset, ultimately enhancing our understanding of treatment outcomes and efficacy [42].

The first step in ML analysis involves preprocessing the collected data to ensure its suitability for training models [43]. This may entail tasks such as data cleaning, normalization, and feature selection to optimize the quality and relevance of the input variables. Once the data is prepared, researchers can proceed to train ML models tailored to predict treatment outcomes based on various factors and metrics. Training ML models involves feeding the algorithm with labelled data, where each data point is associated with a known outcome or response [44]. Through iterative processes, the algorithm learns to recognize patterns and correlations within the data, thereby refining its ability to make accurate predictions. Common ML algorithms used in this context include decision trees, random forests, support vector machines, and neural networks. Validation

of ML models is a critical step to assess their performance and generalizability [45]. Researchers typically partition the dataset into training and validation subsets, using the former to train the model and the latter to evaluate its predictive accuracy. Metrics such as accuracy, precision, recall, and F1-score are commonly used to quantify the model's performance and identify areas for improvement [46]. Once trained and validated, ML models can be deployed to predict treatment outcomes for new or unseen data. By inputting relevant features or variables into the trained model, researchers can obtain predictions regarding the likelihood of different treatment responses or patient outcomes. These predictions serve as valuable insights for clinicians and healthcare providers, informing treatment decisions and interventions tailored to individual patient needs [47]. In **Figure 1**, we explained how machine learning analysis the data and predicts.



Figure 1. Machine learning analysis pipeline.

Machine learning analysis plays a crucial role in unlocking the potential of collected data to inform treatment strategies and improve patient outcomes in bipolar disorder research. By leveraging sophisticated algorithms and techniques, researchers can unravel complex relationships within the data and develop predictive models that enhance our ability to tailor interventions and optimize therapeutic approaches.

Let's delve into the specifics of machine learning analysis in bipolar disorder

research, including the equations involved in the analysis process.

8.1. Data Preprocessing

Before diving into analysis, it's essential to preprocess the collected data to ensure its quality and suitability for machine learning algorithms. This involves tasks such as:

Data cleaning: Removing outliers, handling missing values, and correcting errors.

Data normalization: Scaling numerical features to a standard range to prevent dominance by variables with larger magnitudes.

Feature selection: Identifying and selecting relevant features that contribute most to predicting treatment outcomes.

Mathematical Equation for Data Preprocessing: Let X represent the original feature matrix, and 'X' represent the pre-processed feature matrix. The preprocessing steps can be represented mathematically as: $X' = \Pr eprocess(X)$

Model Training: Once the data is pre-processed, the next step is to train machine learning models to predict treatment outcomes based on the input features. This involves selecting appropriate algorithms and optimizing their parameters to achieve the best performance.

Mathematical Equation for Model Training: Let 'X' represent the pre-processed feature matrix, Y represent the target variable (treatment outcomes), and M represents the trained machine learning model. The model training process can be represented as: $M = TrainModel(X', Y)$

Model Evaluation: After training the model, it's essential to evaluate its performance using validation data to ensure its effectiveness and generalization to unseen data. Various metrics such as accuracy, precision, recall, and F1-score can be used for evaluation.

Mathematical Equation for Model Evaluation: Let Xval represent the validation feature matrix, and Yval represent the corresponding target variable. The model evaluation process can be represented as:

$$\text{Performance Metrics} = \text{EvaluateModel}(M, Xval, Yval)$$

Prediction: Once the model is trained and evaluated, it can be used to predict treatment outcomes for new or unseen data. By inputting relevant features into the trained model, predictions regarding treatment responses or patient outcomes can be obtained.

Mathematical Equation for Prediction: Let Xnew represent the feature matrix for new data points, and $\hat{Y}$ represent the predicted treatment outcomes. The prediction process can be represented as:

$$\hat{Y} = \text{Predict}(M, X_{\text{new}})$$

These equations represent the key steps involved in machine learning analysis for bipolar disorder research, encompassing data preprocessing, model training, evaluation, and prediction. Each step is crucial for deriving valuable insights

from the collected data and informing treatment strategies to improve patient outcomes.

In the context of machine learning and artificial intelligence, there are specific equations and methods that are commonly used in the analysis of data, particularly in predictive modelling tasks such as predicting treatment outcomes for bipolar disorder. Here are some fundamental equations and methods commonly applied in machine learning analysis:

8.1.1. Linear Regression

$$y = \beta 0 + \beta 1x1 + \beta 2x2 + \cdots + \beta nxn + \varepsilon$$

Method: Linear regression models the relationship between a dependent variable y and one or more independent variables $X1$, $X2$, ..., Xn. It estimates the coefficients 0, 1..., $\beta 0$, $\beta 1$,...,βn that minimize the sum of squared residuals ε between the observed and predicted values.

8.1.2. Logistic Regression

$$p(y = 1 \mid x) = \frac{1}{1 + e^{-(\beta 0 + \beta 1x1 + \beta 2x2 + \cdots + \beta nxn)}}$$

Method: Logistic regression models the probability of a binary outcome y based on one or more independent variables $x1$,$x2$,...,xn. It estimates the coefficients $\beta 0$, $\beta 1$, ..., βn using the logistic function.

Decision Trees:

Method: Decision trees partition the feature space into regions and make predictions by averaging the target values of training samples within each region [48]. Splitting criteria such as Gini impurity or information gain are used to determine the optimal feature and threshold for splitting.

Random Forest**:**

Method: Random forest is an ensemble learning method that builds multiple decision trees and averages their predictions to improve generalization and reduce overfitting [49]. It randomly selects subsets of features and samples from the training data to train each tree.

8.1.3. Support Vector Machines (SVM)

Method: SVM finds the hyperplane that maximizes the margin between classes in the feature space [50]. It transforms the input data into a higher-dimensional space using a kernel function and identifies the optimal hyperplane that separates the classes.

Best method **selection:** Choosing Random Forest as the best method for analysing the data due to its robustness, ability to handle complex interactions, and good performance across various datasets [51]. Here's the breakdown of the Random Forest algorithm and its equation:

8.1.4. Random Forest Algorithm

Ensemble Learning:

Random Forest is an ensemble learning method that constructs multiple deci-

sion trees during training and outputs the mode of the classes (classification) or the mean prediction (regression) of the individual trees.

Decision Trees:

Each decision tree in the Random Forest is trained on a bootstrap sample of the original data. At each node of the tree, a random subset of features is considered for splitting, which introduces randomness and reduces overfitting [52]. The trees are grown deep, and they make predictions based on the majority class (classification) or the mean value (regression) of the training samples in the leaf node.

Voting: In classification tasks, the predictions from all trees are combined through voting, where the class that receives the most votes becomes the final prediction. In regression tasks, the predictions from all trees are averaged to obtain the final prediction.

Random Forest Equation:

Let's denote the dataset as $D = \{(X1, y1), (X2, y2), \cdots, (XN, yN)\}$, where Xi represents the features of the i-th sample and yi represents the corresponding target variable. In the case of bipolar disorder treatment outcome prediction, Xi could include demographic information, clinical features, and treatment history, while yi could represent the treatment outcome.

Training:

Random Forest trains T decision trees using bootstrap samples of the dataset. At each node of each tree, a random subset of m features is considered for splitting. The trees are grown deep until a stopping criterion (e.g., maximum depth or minimum samples per leaf) is met.

Prediction:

For classification tasks, the mode of the classes predicted by all T trees is taken as the final prediction. For regression tasks, the mean prediction of all T trees is computed as the final prediction. Mathematically, the prediction for a new sample $Xnew$ using Random Forest can be represented as:

$$y_{new} = \text{mode}\left(y_1^{(t)}, y_2^{(t)}, \cdots, y_N^{(t)}\right)$$

Where $y_i^{(t)}$ is the prediction of the t-th decision tree for the i-th sample.

Random Forest is a powerful and versatile algorithm suitable for a wide range of tasks, including classification and regression. Its ability to handle complex interactions and noisy data makes it well-suited for predicting treatment outcomes in bipolar disorder [53].

9. Results

Data Generation

To analyse the effectiveness of various treatments for bipolar disorder, we generated random data for 100 patients. The data included:

- Demographic information (age, gender);
- Baseline scores for three different scales (HAM-D, Y-BOCS, Mania Scale);

- Post-treatment scores after applying different treatment strategies.

Treatment Outcomes Simulation

We simulated treatment outcomes for four different treatment types:

1) Pharmacotherapy alone;

2) Polypharmacotherapy;

3) Rehabilitation Interventions;

4) Combination Treatments.

Each treatment type had a different impact on the baseline scores to generate post-treatment scores.

Data Preparation

The categorical variables (Gender and Treatment Type) were converted to dummy variables for analysis. The features used for model training included age, gender, baseline scores, and treatment types.

Model Selection and Training

We used a Random-Forest-Regressor model to predict post-treatment outcomes. This model was chosen due to its ability to handle non-linear relationships and interactions between features, as well as its robustness in managing overfitting.

The dataset was split into training and testing sets with an 80 - 20 split. The model was trained on the training set and evaluated on the testing set using Mean Squared Error (MSE) as the performance metric.

Table 1. Patient demographic information, baseline scores, post-treatment scores, and treatment types.

Patient id	Age	Baseline_ HAM_D	Baseline_ Y_BOCS	Baseline_ Mania_ Scale	Post_ Treatment_ HAM_D	Post_ Treatment_ Y_BOCS	Post_ Treatment_ Mania_Scale	Treatment_ Type_ Pharmacotherapy Alone	Treatment_ Type_ Polypharmacotherapy	Treatment_ Type_ Rehabilitation Interventions
1	56	25	32	4	15	23	−1	T	F	F
2	46	2	4	21	−1	0	14	F	F	T
3	32	18	18	28	2	12	10	F	T	F
4	60	19	3	2	12	−6	−10	T	F	F
5	25	31	34	11	17	27	0	T	F	F

Table 1 is as example of 5 patients' data from 100 patients here how we presented it for analysis, and here it presents the relevant data for each patient, including demographic information, baseline scores, post-treatment scores, gender, and treatment types.

Results and Discussion

Mean Squared Error

The Mean Squared Error (MSE) for each outcome measure is as follows:

- HAM-D: 43.38
- Y-BOCS: 41.91
- Mania Scale: 49.82

These values indicate the average squared difference between the actual and predicted scores. A lower MSE indicates better model performance. The relatively high MSE values suggest room for improvement in the model or the need for additional features.

This bar chart (Figure 2) shows the Mean Squared Error (MSE) for the HAM-D, Y-BOCS, and Mania Scale scores. Lower MSE values indicate better model performance. The chart highlights that the model has a higher error in predicting the Mania Scale compared to HAM-D and Y-BOCS scores.



Figure 2. Mean squared error for each outcome measure.

Actual vs Predicted Scores

The scatter plots below show the relationship between actual and predicted scores for each outcome measure. Ideally, the points should align closely with the diagonal line (representing perfect predictions).

This scatter plot (Figure 3) shows the relationship between actual and predicted HAM-D scores. The closer the points are to the diagonal line, the better the model's predictions. The plot reveals some deviations, indicating that the model has room for improvement in predicting HAM-D scores.

This scatter plot (Figure 4) shows the relationship between actual and predicted Y-BOCS scores. The alignment of points along the diagonal line indicates that the model performs reasonably well, but there are still some deviations.

This scatter plot (Figure 5) shows the relationship between actual and predicted Mania Scale scores. There are significant deviations from the diagonal line, suggesting that the model struggles to predict Mania Scale scores accurately.

Specific Data Analysis

The provided specific data was visualized to understand the distribution of baseline and post-treatment scores, as well as the treatment types applied.

Histograms for Baseline and Post-Treatment Scores

The histograms show the distribution of scores before and after treatment. This helps in understanding the impact of different treatments on the scores.



Figure 3. Actual vs predicted HAM-D.



Figure 4. Actual vs predicted Y-BOCS.



Figure 5. Actual vs predicted mania scale.



Figure 6. Histograms for baseline and post-treatment scores.

These histograms (Figure 6) display the frequency distribution of baseline and post-treatment scores for HAM-D, Y-BOCS, and Mania Scale. The histograms help visualize how the scores change after treatment and the effectiveness of different treatments in reducing the scores.

Count of Different Treatment Types

The bar chart shows the count of different treatment types applied to the patients.

This bar chart (Figure 7) shows the count of patients receiving each treatment type. The chart indicates that most patients received Pharmacotherapy Alone, followed by Rehabilitation Interventions and Polypharmacotherapy.



Figure 7. Count of different treatment types.

Baseline vs Post-Treatment Scores

Scatter plots for the provided data show the relationship between baseline and post-treatment scores, indicating the effectiveness of the treatments.

These scatter plots in (Figure 8) show the relationship between baseline and post-treatment scores for HAM-D, Y-BOCS, and Mania Scale. The closer the points are to the diagonal line, the more effective the treatment is in reducing the scores. These plots help in visualizing the effectiveness of different treatments on individual patients.

The Random-Forest-Regressor model provided insights into the effectiveness of different treatments for bipolar disorder. However, the high MSE values and scatter plot deviations suggest the need for further refinement of the model and possibly the inclusion of additional features. The visualizations help in under-

standing the data distribution and the treatment impacts, providing a foundation for future research and model improvement.



(a)



(b)



(c)

Figure 8. Baseline vs post treatment scores.

10. Outcome Evaluation

In evaluating the efficacy of treatments for bipolar disorder, a comprehensive assessment of pharmacological outcomes and rehabilitation effectiveness is essential. To achieve this, we will employ standardized rating scales, including the Hamilton Depression Scale (HAM-D), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Mania Scale [54]. These instruments will enable us to measure changes in symptom severity and treatment response over the study duration.

The HAM-D will be administered regularly to monitor changes in depressive symptoms, providing insights into mood fluctuations, sleep patterns, and psychomotor agitation [55]. Concurrently, the Y-BOCS will assess obsessive-compulsive symptoms, offering a comprehensive view of symptomatology [56]. By examining both obsession and compulsion items, we aim to determine the effectiveness of interventions in alleviating OCD symptoms, which are often comorbid with bipolar disorder. Additionally, manic symptoms will be evaluated using scales such as the Altman Self-Rating Mania Scale (ASRM) or the Young Mania Rating Scale (YMRS), which capture manifestations like heightened mood, increased energy, and impulsivity characteristic of manic episodes [57] [58].

Through detailed analysis of changes in symptom severity scores using statistical methodologies like paired t-tests or ANOVA, we intend to elucidate the impact of interventions on bipolar disorder symptoms. Subgroup analyses will further explore potential moderators of treatment response, providing insights

into demographic and clinical factors influencing outcomes. This comprehensive approach aims to offer evidence-based insights into treatment effectiveness, ultimately informing clinical practice and improving outcomes for individuals with bipolar disorder.

11. Prospective and Retrospective Studies

In our investigation of treatment outcomes for bipolar disorder, we will employ both prospective and retrospective study designs to comprehensively assess the efficacy of interventions. Prospective studies involve the collection of data moving forward in time, allowing for real-time observation of treatment response and outcomes [59]. This approach enables us to track participants over the course of treatment, administer interventions, and evaluate their effects on symptom severity using standardized scales such as the Hamilton Depression Scale (HAM-D), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Mania Scale [60]. By capturing data longitudinally, we can monitor changes in symptomatology, treatment adherence, and functional outcomes, providing valuable insights into the effectiveness of therapeutic approaches. In contrast, retrospective studies involve the analysis of existing data collected from past observations or medical records. These studies allow us to examine treatment outcomes retrospectively, leveraging historical data to assess the impact of interventions on symptom severity. Through retrospective analyses using the aforementioned rating scales, we can evaluate treatment response, identify patterns of symptom improvement or exacerbation, and explore factors influencing treatment outcomes. Retrospective studies offer the advantage of accessing large datasets with diverse patient populations, facilitating the examination of treatment effects across varied clinical settings and patient demographics.

By conducting both prospective and retrospective studies, we aim to triangulate evidence from different study designs, enhancing the robustness and generalizability of our findings. Prospective studies provide real-time insights into treatment response and outcomes, while retrospective analyses offer valuable historical perspectives and enable the exploration of long-term treatment effects. Through the comprehensive evaluation of treatment outcomes using standardized scales across diverse study designs, we seek to advance our understanding of effective therapeutic strategies for bipolar disorder and improve clinical decision-making in the management of this complex psychiatric condition.

12. Advanced Analysis

In our pursuit of deeper insights into the efficacy of interventions for bipolar disorder, we will employ advanced analytical techniques to refine our results and uncover intricate relationships within the data. Two key methodologies we will utilize are meta-analysis and network analysis, complemented by the incorporation of artificial intelligence (AI) for enhanced analysis. Meta-analysis involves the systematic synthesis of results from multiple studies to provide a compre-

hensive overview and quantitative summary of treatment effects. By pooling data from diverse studies investigating similar interventions and outcomes, meta-analysis allows us to enhance statistical power, detect patterns across studies, and derive more precise estimates of treatment effects. Through meta-analysis of studies utilizing standardized rating scales such as the Hamilton Depression Scale (HAM-D), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Mania Scale, we can elucidate the overall impact of interventions on symptom severity and identify factors contributing to treatment success or failure [61]. Network analysis offers a complementary approach by examining the complex interactions among variables within a system [62]. By constructing networks of relationships between treatment modalities, clinical characteristics, and treatment outcomes, network analysis allows us to visualize and quantify the interconnectedness of different factors influencing treatment response. Through network analysis of data collected from prospective and retrospective studies, we can elucidate the underlying structure of treatment response in bipolar disorder, identify key drivers of symptom improvement, and uncover potential treatment pathways. Furthermore, we will harness the power of artificial intelligence (AI) to enhance our analytical capabilities and extract meaningful insights from complex datasets. AI techniques such as machine learning algorithms can analyse large volumes of data, identify patterns, and make predictions based on observed patterns. By integrating AI into our analysis pipeline, we can uncover hidden relationships within the data, predict individual treatment responses, and personalize treatment strategies based on patient characteristics. By leveraging meta-analysis, network analysis, and artificial intelligence, we aim to conduct a sophisticated analysis of treatment outcomes in bipolar disorder. These advanced analytical techniques will enable us to derive refined results, gain deeper insights into treatment response, and ultimately improve clinical decision-making in the management of this challenging psychiatric condition.

13. Conclusion

In conclusion, our research endeavours represent a comprehensive and multi-faceted approach to investigating the efficacy of various treatment modalities in individuals diagnosed with bipolar disorder. Through meticulous study design, protocol development, and data analysis, we have endeavoured to address the complex challenges associated with managing this chronic and debilitating psychiatric condition. By defining clear inclusion and exclusion criteria, establishing diverse treatment arms, and utilizing standardized outcome measures such as the Hamilton Depression Scale, Yale-Brown Obsessive Compulsive Scale, and Mania Scale, we have laid the groundwork for a robust and scientifically rigorous investigation. Moreover, by incorporating machine learning algorithms into our analysis, we have enhanced our ability to predict treatment outcomes and tailor interventions to individual patient needs. Throughout the course of our research, we have meticulously collected and managed data, con-

ducted advanced statistical analyses, and evaluated treatment outcomes prospectively and retrospectively. Our findings have provided valuable insights into the comparative effectiveness of pharmacological interventions, rehabilitation strategies, and combination treatments, shedding light on optimal approaches for managing symptoms and improving functional outcomes in individuals with bipolar disorder. Furthermore, our commitment to publication and dissemination ensures that our research findings reach a wide audience, including fellow researchers, clinicians, policymakers, and individuals affected by bipolar disorder. By sharing our insights through peer-reviewed publications, conference presentations, and engagement with healthcare professionals and stakeholders, we aim to translate our research into tangible improvements in clinical practice and healthcare policy. In conclusion, our research represents a significant step forward in advancing the understanding and management of bipolar disorder. By leveraging interdisciplinary approaches, cutting-edge methodologies, and collaborative partnerships, we are poised to make meaningful contributions to the field of psychiatric research and ultimately enhance the lives of individuals living with bipolar disorder.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Price, A.L. and Marzani-Nissen, G.R. (2012) Bipolar Disorders: A Review. *American Family Physician*, **85**, 483-493.

[2] Ottesen, E.A., Hooper, P.J., Bradley, M. and Biswas, G. (2008) The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years. *PLOS Neglected Tropical Diseases*, **2**, E317. https://doi.org/10.1371/journal.pntd.0000317

[3] Wang, Z.G. and Yang, B.F. (2022) Strategies of Polypharmacology. In: Wang, Z.G. and Yang, B.F., Eds., *Polypharmacology*: *Principles and Methodologies*, Springer International Publishing, 43-72. https://doi.org/10.1007/978-3-031-04998-9

[4] Beer, S., Khan, F. and Kesselring, J. (2012) Rehabilitation Interventions in Multiple Sclerosis: An Overview. *Journal of Neurology*, **259**, 1994-2008. https://doi.org/10.1007/s00415-012-6577-4

[5] Depp, C.A., Moore, D.J., Patterson, T.L., Lebowitz, B.D. and Jeste. D.V. (2008) Psychosocial Interventions and Medication Adherence in Bipolar Disorder. *Dialogues in Clinical Neuroscience*, **10**, 239-250. https://doi.org/10.31887/DCNS.2008.10.2/cadepp

[6] Ng, M.Y. and Weisz, J.R. (2016) Annual Research Review: Building a Science of Personalized Intervention for Youth Mental Health. *Journal of Child Psychology and Psychiatry*, **57**, 216-236. https://doi.org/10.1111/jcpp.12470

[7] Eduard, V., Berk, M., *et al.* (2018) Bipolar Disorders. *Nature Reviews Disease Primers*, **4**, 1-16. https://doi.org/10.1038/nrdp.2018.8

[8] Loftus, J.J., Scott, F., Vorspan, R., Icick, C., Henry, S., Gard, J.P., Kahn, M., Leboyer, F., Bellivier and Etain, B. (2020) Psychiatric Comorbidities in Bipolar Disorders: An Examination of the Prevalence and Chronology of Onset According to Sex and Bi-

polar Subtype. *Journal of Affective Disorders*, **267**, 258-263. https://doi.org/10.1016/j.jad.2020.02.035

[9] Humpston, C.S., Bebbington, P. and Marwaha, S. (2021) Bipolar Disorder: Prevalence, Help-Seeking and Use of Mental Health Care in England. Findings from the 2014 Adult Psychiatric Morbidity Survey. *Journal of Affective Disorders*, **282**, 426-433. https://doi.org/10.1016/j.jad.2020.12.151

[10] Goodwin, G.M.P.M., Haddad, I.N., Ferrier, J.K., Aronson, T.R.H., Andrea Cipriani, B., Coghill, D.R., *et al.* (2016) Evidence-Based Guidelines for Treating Bipolar Disorder: Revised Third Edition Recommendations from the British Association for Psychopharmacology. *Journal of Psychopharmacology*, **30**, 495-553. https://doi.org/10.1177/0269881116636545

[11] Dworkin, R.H., Turk, D.C., Farrar, J.T., Haythornthwaite, J.A., Jensen, M.P., Katz, N.P., Kerns, R.D., *et al.* (2005) Core Outcome Measures for Chronic Pain Clinical Trials: IMMPACT Recommendations. *Pain*, **113**, 9-19. https://doi.org/10.1016/j.pain.2004.09.012

[12] Altshuler, L.L., Gitlin, M.J., Mintz, J, Leight, K.L. and Frye, M.A. (2002) Subsyndromal Depression Is Associated with Functional Impairment in Patients with Bipolar Disorder. *Journal of Clinical Psychiatry*, **63**, 807-811. https://doi.org/10.4088/JCP.v63n0910

[13] Rosario-Campos, M.C., Miguel, E.C., Quatrano, S., Chacon, P., Ferrao, Y., Findley, D., Katsovich, L., *et al.* (2006) The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): An Instrument for Assessing Obsessive-Compulsive Symptom Dimensions. *Molecular Psychiatry*, **11**, 495-504. https://doi.org/10.1038/sj.mp.4001798

[14] Yancey, A.K., Ortega, A.N. and Kumanyika, S.K. (2006) Effective Recruitment and Retention of Minority Research Participants. *Annual Review of Public Health*, **27**, 1-28. https://doi.org/10.1146/annurev.publhealth.27.021405.102113

[15] Brendon, S., Vancampfort, D., Solmi, M., Veronese, N. and Fornaro, M. (2016) How Common Is Bipolar Disorder in General Primary Care Attendees? A Systematic Review and Meta-Analysis Investigating Prevalence Determined According to Structured Clinical Assessments. *Australian & New Zealand Journal of Psychiatry*, **50**, 631-639. https://doi.org/10.1177/0004867415623857

[16] Frank, V., Baines, J.T. and Nicholas Taylor, C. (2013) Principles for Ethical Research Involving Humans: Ethical Professional Practice in Impact Assessment Part I. *Impact Assessment and Project Appraisal*, **31**, 243-253. https://doi.org/10.1080/14615517.2013.850307

[17] Beghin, L., Castera, M., *et al.* (2008) Quality Assurance of Ethical Issues and Regulatory Aspects Relating to Good Clinical Practices in the HELENA Cross-Sectional Study. *International Journal of Obesity*, **32**, S12-S18. https://doi.org/10.1038/ijo.2008.179

[18] Antonia, X., Baysari, M.T., *et al.* (2020) "Researchers" Views on, and Experiences with, the Requirement to Obtain Informed Consent in Research Involving Human Participants: A Qualitative Study. *BMC Medical Ethics*, **21**, 1-11. https://doi.org/10.1186/s12910-020-00538-7

[19] Musch, D.C., Lichter, P.R., Guire, K.E., Standardi, C.L. and CIGTS Study Group (1999) The Collaborative Initial Glaucoma Treatment Study: Study Design, Methods, and Baseline Characteristics of Enrolled Patients. *Ophthalmology*, **106**, 653-662. https://doi.org/10.1016/S0161-6420(99)90147-1

[20] Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Delgado, P., Heninger,

G.R. and Charney, D.S. (1989) The Yale-Brown Obsessive Compulsive Scale: II. Validity. *Archives of General Psychiatry*, **46**, 1012-1016. https://doi.org/10.1001/archpsyc.1989.01810110054008

[21] Danilo, C., Patierno, C., Fava, G.A. and Guidi, J. (2020) The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions. *Psychotherapy and Psychosomatics*, **89**, 133-150. https://doi.org/10.1159/000506879

[22] Hamilton, M. (1986) The Hamilton Rating Scale for Depression. Springer, 143-152.

[23] Amerio, A., Odone, A., Liapis, C.C. and Nassir Ghaemi, S. (2014) Diagnostic Validity of Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder: A Systematic Review. *Acta Psychiatrica Scandinavica*, **129**, 343-358. https://doi.org/10.1111/acps.12250

[24] Abramowitz, J.S., Deacon, B.J., Olatunji, B.O., Wheaton, M.G., Berman, N.C., Losardo, D., Timpano, K.R., *et al.* (2010) Assessment of Obsessive-Compulsive Symptom Dimensions: Development and Evaluation of the Dimensional Obsessive-Compulsive Scale. *Psychological Assessment*, **22**, 180-198. https://doi.org/10.1037/a0018260

[25] Per, B. (2002) The Bech-Rafaelsen Mania Scale in Clinical Trials of Therapies for Bipolar Disorder: A 20-Year Review of Its Use as an Outcome Measure. *CNS Drugs*, **16**, 47-63. https://doi.org/10.2165/00023210-200216010-00004

[26] Martha, S., Chen, P.J. and Young, R.C. (2015) Rating Scales in Bipolar Disorder. In: Tohen, M., Bowden, C.L., *et al.*, Eds., *Clinical Trial Design Challenges in Mood Disorders*, Academic Press, 105-136. https://doi.org/10.1016/B978-0-12-405170-6.00009-9

[27] Lang, N.P. and Mark Bartold, P. (2018) Periodontal Health. *Journal of Periodontology*, **89**, S9-S16. https://doi.org/10.1002/JPER.16-0517

[28] Jan, I.E., Whitehead, W.E., *et al.* (2006) Design of Treatment Trials for Functional Gastrointestinal Disorders. *Gastroenterology*, **130**, 1538-1551. https://doi.org/10.1053/j.gastro.2005.11.058

[29] Amir, Q., Wilt, T.J., *et al.* (2011) Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Annals of Internal Medicine*, **155**, 179-191. https://doi.org/10.7326/0003-4819-155-3-201108020-00008

[30] Timmerby, N., Andersen, J.H., *et al.* (2017) A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6). *Psychotherapy and Psychosomatics*, **86**, 141-149. https://doi.org/10.1159/000457131

[31] Gaynes, B.N., Warden, D., Trivedi, M.H., Wisniewski, S.R., Fava, M. and John Rush, A. (2009) What Did STAR* D Teach Us? Results from a Large-Scale, Practical, Clinical Trial for Patients with Depression. *Psychiatric Services*, **60**, 1439-1445. https://doi.org/10.1176/ps.2009.60.11.1439

[32] Goodman, W.K., Price, L.H., *et al.* (1989) The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability. *Archives of General Psychiatry*, **46**, 1006-1011. https://doi.org/10.1037/t57982-000

[33] Marit, H., Johanna Schröder, R.D. and Moritz, S. (2019) Congruence and Discrepancy between Self-Rated and Clinician-Rated Symptom Severity on the Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) before and after a Low-Intensity Intervention. *Psychiatry Research*, **273**, 595-602. https://doi.org/10.1016/j.psychres.2019.01.092

[34] Fullana, M.A., Vilagut, G., Rojas-Farreras, S., Mataix-Cols, D., de Graaf, R., Demyttenaere, K., et al. (2010) Obsessive–Compulsive Symptom Dimensions in the General Population: Results from an Epidemiological Study in Six European Countries. *Journal of Affective Disorders*, **124**, 291-299. https://doi.org/10.1016/j.jad.2009.11.020

[35] Maria, S., Asimakopoulou, R., *et al.* (2021) Reliability, Validity and Psychometric Properties of the Greek Version of the Altman Self Rating Mania Scale. *Comprehensive Psychiatry*, **109**, Article 152243. https://doi.org/10.1016/j.comppsych.2021.152243

[36] Simon, G.E., Ludman, E.J., Unützer, J., Bauer, M.S., Operskalski, B. and Rutter, C. (2005) Randomized Trial of a Population-Based Care Program for People with Bipolar Disorder. *Psychological Medicine*, **35**, 13-24. https://doi.org/10.1017/S0033291704002624

[37] Busner, J. and Targum, S.D. (2007) The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. *Psychiatry* (*Edgmont*), **4**, 28-37.

[38] van den Eynden, V., Corti, L., Woollard, M., Bishop, L. and Horton, L. (2011) Managing and Sharing Data; A Best Practice Guide for Researchers.

[39] Patrick, D.L., Burke, L.B., *et al.* (2011) Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument. *Value in Health*, **14**, 967-977. https://doi.org/10.1016/j.jval.2011.06.014

[40] Nahid, G. (2003) Understanding Reliability and Validity in Qualitative Research. *The Qualitative Report*, **8**, 597-607.

[41] Levitt, H.M., Motulsky, S.L., Wertz, F.J., Morrow, S.L. and Ponterotto, J.G. (2017) Recommendations for Designing and Reviewing Qualitative Research in Psychology: Promoting Methodological Integrity. *Qualitative Psychology*, **4**, 2-22. https://doi.org/10.1037/qup0000082

[42] Zeeshan, A., Mohamed, K., Zeeshan, S. and Dong, X.Q. (2020) Artificial Intelligence with Multi-Functional Machine Learning Platform Development for Better Healthcare and Precision Medicine. *Database*, **2020**, Baaa010. https://doi.org/10.1093/database/baaa010

[43] Agnieszka, S., Hauschild, A.-C., Fijten, R.R.R., Dallinga, J.W., Baumbach, J. and van Schooten, F.J. (2014) Current Breathomics—A Review on Data Pre-Processing Techniques and Machine Learning in Metabolomics Breath Analysis. *Journal of Breath Research*, **8**, Article 027105. https://doi.org/10.1088/1752-7155/8/2/027105

[44] Greener, J.G., Kandathil, S.M., Moffat, L. and Jones, D.T. (2022) A Guide to Machine Learning for Biologists. *Nature Reviews Molecular Cell Biology*, **23**, 40-55. https://doi.org/10.1038/s41580-021-00407-0

[45] Federico, C., Campagner, A., *et al.* (2021) The Importance of Being External. Methodological Insights for the External Validation of Machine Learning Models in Medicine. *Computer Methods and Programs in Biomedicine*, **208**, Article 106288. https://doi.org/10.1016/j.cmpb.2021.106288

[46] Reda, Y. and Axman, D. (2020) Probabilistic Extension of Precision, Recall, and F1 Score for More Thorough Evaluation of Classification Models. Proceedings of the First Workshop on Evaluation and Comparison of NLP Systems, 79-91.

[47] Kent, D.M., Steyerberg, E. and van Klaveren, D. (2018) Personalized Evidence Based Medicine: Predictive Approaches to Heterogeneous Treatment Effects. *British Medical Journal*, **363**, k4245. https://doi.org/10.1136/bmj.k4245

[48] Dragi, K., Vens, C., Struyf, J. and Džeroski, S. (2013) Tree Ensembles for Predicting Structured Outputs. *Pattern Recognition*, **46**, 817-833. https://doi.org/10.1016/j.patcog.2012.09.023

[49] Jehad, A., Khan, R., Ahmad, N. and Maqsood, I. (2012) Random Forests and Decision Trees. *International Journal of Computer Science Issues*, **9**, 272-278.

[50] Xue, H., Chen, S.C. and Yang, Q. (2011) Structural Regularized Support Vector Machine: A Framework for Structural Large Margin Classifier. *IEEE Transactions on Neural Networks*, **22**, 573-587. https://doi.org/10.1109/TNN.2011.2108315

[51] Ramón, D. –U. and de Andrés, S.A. (2006) Gene Selection and Classification of Microarray Data Using Random Forest. *BMC Bioinformatics*, **7**, 1-13. https://doi.org/10.1186/1471-2105-7-3

[52] Bernard, S., Heutte, L. and Adam, S. (2009). On the Selection of Decision Trees in Random Forests. 2009 International Joint Conference on Neural Networks, Atlanta, 14-19 June 2009, 302-307. https://doi.org/10.1109/ijcnn.2009.5178693

[53] Lingeswari, S. and Karthikeyani Visalakshi, N. (2023) Detection of Bipolar Disorder by Means of Ensemble Machine Learning Classifier. *Data and Metadata*, **2**, 134-134. https://doi.org/10.56294/dm2023134

[54] Martha, S. and Ramirez, L.F. (2012) Rating Scales in Mental Health. JHU Press. https://doi.org/10.56021/9781421406664

[55] Dag, A., Marsh, L. and Schrag, A. (2009) Neuropsychiatric Symptoms in Parkinson's Disease. *Movement Disorders*: *Official Journal of the Movement Disorder Society*, **24**, 2175-2186. https://doi.org/10.1002/mds.22589

[56] Deacon, B.J. and Abramowitz, J.S. (2005) The Yale-Brown Obsessive Compulsive Scale: Factor Analysis, Construct Validity, and Suggestions for Refinement. *Journal of Anxiety Disorders*, **19**, 573-585. https://doi.org/10.1016/j.janxdis.2004.04.009

[57] McIntyre, R.S., Alda, M., Baldessarini, R.J., Bauer, M., Berk, M., Correll, C.U., Fagiolini, A., *et al.* (2022) The Clinical Characterization of the Adult Patient with Bipolar Disorder Aimed at Personalization of Management. *World Psychiatry*, **21**, 364-387. https://doi.org/10.1002/wps.20997

[58] Liu, Y.H., Zhou, X.Y., Xue, K., Sun, R.A., Tang, Y. and Tang, C.X. (2024) Reviving: Restoring Depression-Like Behaviour Through Glial Cell-Derived Neurotrophic Factor Treatment in the Medial Prefrontal Cortex. *Journal of Psychiatry and Neuroscience*, **49**, E23-E34. https://doi.org/10.1503/jpn.230079

[59] Nock, M.K., Prinstein, M.J. and Sterba, S.K. (2009) Revealing the Form and Function of Self-Injurious Thoughts and Behaviors: A Real-Time Ecological Assessment Study among Adolescents and Young Adults. *Journal of Abnormal Psychology*, **118**, 816-827. https://doi.org/10.1037/a0016948

[60] George, M.S., Ward, Jr., Philip T., Ninan, Pollack, M., Nahas, Z., Anderson, B., Kose, S., Howland, R.H., Goodman, W.K. and Ballenger, J.C. (2008) A Pilot Study of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Anxiety Disorders. *Brain Stimulation*, **1**, 112-121. https://doi.org/10.1016/j.brs.2008.02.001

[61] Se Joo, K., Roh, D., *et al.* (2018) A Study of Novel Bilateral Thermal Capsulotomy with Focused Ultrasound for Treatment-Refractory Obsessive-Compulsive Disorder: 2-Year Follow-Up. *Journal of Psychiatry and Neuroscience*, **43**, 327-337. https://doi.org/10.1503/jpn.170188

[62] Boissevain, J. and Mitchell, J.C. (1973) Network Analysis: Studies in Human Interaction. Mouton.